Does tumour necrosis factor α influence insulin sensitivity in skeletal muscle?
Skeletal muscle is the primary site for insulin-stimulated glucose uptake. Insulin resistance, and in particular resistance to the actions of insulin in skeletal muscle, is a major factor in the pathogenesis of Type II diabetes. Insulin increases glucose transport in skeletal muscle by inducing the translocation of GLUT4 (the major insulinregulated glucose transporter) from intracellular vesicles to the plasma membrane. Although expression of the GLUT4 gene is normal in skeletal muscle from patients with Type II diabetes, defective insulin action is associated with impaired trafficking and function of GLUT4. Insulin signalling involves a cascade of events initiated by insulin binding to its cell-surface receptor. This is followed by receptor autophosphorylation and activation of receptor tyrosine kinases, which result in tyrosine phosphorylation of insulin receptor substrates (IRSs), including IRS-1, IRS-2, IRS-3, IRS-4, Gab1 and Shc. Binding of IRSs to the regulatory subunit of phosphoinositide 3-kinase (PI 3-kinase) at Src homology 2 (SH2) domains results in activation of PI 3-kinase, which is necessary for insulin action on glucose transport. PI 3-kinase activation is responsible, at least in part, for insulin stimulation of GLUT4 translocation from intracellular vesicles to the plasma membrane. Insulin-stimulated PI 3-kinase activity is decreased in lean subjects with Type II diabetes, suggesting that a defect in insulin signalling could contribute to impaired GLUT4 translocation and insulin resistance. However, the mechanism(s) contributing to reduced insulinmediated glucose uptake in people with Type II diabetes and insulin resistance are poorly understood. Despite a marked increase in our knowledge about insulin signalling mechanisms, the downstream pathways by which impaired insulin-stimulated activation of PI 3-kinase results in decreased GLUT4 translocation are poorly understood.
Obesity (body mass index 30 kg\m#) is associated with a substantial increase in the relative risk of developing diabetes. Many cytokines are expressed by adipose tissue, and because some of these cytokines, such as tumour necrosis factor α (TNFα), have been shown to reduce insulin-stimulated glucose uptake in adipocytes, it has been suggested that increased cytokine production may contribute to insulin resistance in Type II diabetes. Although there is a body of evidence showing that TNFα reduces insulin-stimulated glucose uptake, and also increases lipolysis in adipose tissue, there is less convincing evidence to support a causal relationship between TNFα and insulin resistance in skeletal muscle. Since reduced insulin-mediated glucose uptake in skeletal muscle is a cardinal feature of insulin resistance in Type II diabetes, it is important to determine whether TNFα causes insulin resistance in skeletal muscle.
Investigators have used both human skeletal muscle cells and rat myoblasts to determine whether TNFα causes resistance to glucose uptake stimulated by insulin signalling pathways in skeletal muscle. Rat L6 myoblasts contain receptors for TNFα, and it has been shown, perhaps surprisingly, that TNFα weakly stimulated glucose uptake (by 3-fold) after 48 h of incubation [1] . By comparison, insulin-like growth factor-I (IGF-I) maximally stimulated glucose uptake by 7-fold after a 24 h incubation. Furthermore, the IGF-I receptor β-subunit, IRS-1 and mitogen-activated protein (MAP) kinase were all phosphorylated in response to IGF-I after only 10 min of incubation. Whereas, in contrast, incubation with TNFα failed to phosphorylate either the IGF-I receptor β-subunit or IRS-1, but did phosphorylate MAP kinase to the same extent as did IGF-I. Despite similar TNFα-induced MAP kinase phosphorylation (compared with IGF-I-induced MAP kinase phosphorylation), TNFα stimulated glucose uptake less than did IGF-I. Thus these results suggest that MAP kinase phosphorylation is not sufficient for glucose uptake in L6 myoblasts, and that TNFα-stimulated glucose uptake may utilize an alternative pathway (compared with IGF-1).
The effects of TNFα on glucose uptake and glycogen synthase activity have also been studied in human skeletal muscle cell cultures from both non-diabetic subjects and subjects with Type II diabetes [2] . In muscle cells from non-diabetic subjects, acute (90-min) exposure to TNFα (5 ng\ml), also perhaps surprisingly, stimulated glucose uptake (73p14 % increase) to a greater extent than did insulin (37p4 % increase ; P 0.02). The acute uptake response to TNFα in cells from subjects with diabetes (51p6 % increase) was also greater than that to insulin (31p3 % increase ; P 0.05). Prolonged (24-h) exposure of cells from non-diabetic subjects to TNFα resulted in a further stimulation of uptake (152p31%; P 0.05), whereas the increase in cells from subjects with Type II diabetes was not significant compared with that in cells receiving acute treatment. After TNFα treatment, the level of GLUT1 protein was elevated in cells from nondiabetic subjects (4.6-fold increase) and in those from subjects with Type II diabetes (1.7-fold increase). In contrast, acute TNFα treatment had no effect on the fractional velocity of glycogen synthase in cells from either non-diabetic subjects or those with Type II diabetes, whereas prolonged exposure reduced the glycogen synthase fractional velocity in cells from both groups of subjects. Therefore, in summary, both acute and prolonged treatment with TNFα up-regulates glucose uptake activity in cultured human muscle cells, but reduces glycogen synthase activity.
In this issue of Clinical Science, Patiag et al. [3] have studied the effects of TNFα and inhibition of protein kinase C on insulin-stimulated glucose uptake. In contrast with other investigators, Patiag et al. [3] investigated the effects of TNFα on : (a) basal glucose uptake and (b) glucose uptake in the presence of increasing concentrations of insulin in L6 myoblasts. They concluded that TNFα does not affect insulin-independent glucose uptake, because they show no change in glucose uptake in the basal state. Futhermore, Patiag et al. [3] conclude that insulin-stimulated glucose uptake was also not affected. Insulin sensitivity was examined in the presence of high (10 ng\ml) and low (1 ng\ml) concentrations of TNFα. The authors calculated the insulin concentrations required to increase glucose uptake by 50 % in the presence of either concentration of TNFα. Their conclusions were that insulin sensitivity was unaffected by either TNFα concentration, suggesting that TNFα does not affect insulin-stimulated glucose uptake and thereby does not cause insulin resistance in skeletal muscle cells. Patiag et al. [3] determined whether various concentrations of insulin increased glucose uptake in the presence of high or low concentrations of TNFα. Incubation with high TNFα levels produced an increase (albeit nonsignificant) in insulin sensitivity (lower insulin concentrations were required to increase glucose uptake by 50 %). However, the standard error around the mean was large with the high concentration of TNFα [(4.37p4.0)i10 −) M, compared with (7.08p1.3)i 10 −) M for the control]. Thus the large variation around the mean may have produced a type 2 statistical error.
What can we learn from this work ? Importantly, Patiag et al. [3] provide convincing evidence that TNFα does not decrease insulin sensitivity. Non-specific inhibition of protein kinase C markedly attenuated glucose uptake, but there was no effect of TNFα. Taking the work of Patiag et al. [3] in conjunction with the published evidence, we can tentatively conclude that TNFα is expressed in adipocytes and induces insulin resistance in adipocytes. However, in skeletal muscle, both acute and prolonged treatment with TNFα has no effect, or perhaps even increases glucose uptake. It is possible to speculate that increased skeletal muscle glucose uptake mediated by TNFα could be a compensatory mechanism that attenuates the impact of reduced insulin-stimulated glucose uptake in Type II diabetes.
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